JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1998; 31:1460-1465
© 1998 by the American College of Cardiology Foundation
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morrow, D.
Right arrow Articles by Braunwald, E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morrow, D.
Right arrow Articles by Braunwald, E

C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction

DA Morrow, N Rifai, EM Antman, DL Weiner, CH McCabe, CP Cannon, and E Braunwald

Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. damorrow@bics.bwh.harvard.edu

OBJECTIVES: We evaluated C-reactive protein (CRP) alone and in conjunction with a rapid qualitative assay for cardiac-specific troponin T (cTnT) for predicting 14-day mortality in patients with unstable angina or non-Q wave myocardial infarction (NQMI). BACKGROUND: Elevated CRP has been found to correlate with higher risk for cardiac events in patients with coronary disease. METHODS: At enrollment into the Thrombolysis in Myocardial Infarction (TIMI) 11A trial, a dose-ranging trial of enoxaparin for unstable angina and NQMI, serum was obtained for CRP measurement and rapid cTnT assay. RESULTS: Quantitative CRP and rapid cTnT assays were performed in all patients. CRP was higher among patients who died than in survivors (7.2 vs. 13 mg/dl, p = 0.0038). The probability of a positive rapid cTnT assay rose with increasing CRP concentration (p < 0.0001). Among patients with a negative rapid cTnT assay, the mortality rate was higher among patients with CRP > or = 1.55 mg/dl (5.80% vs. 0.36%, p = 0.006). Patients with both an early positive rapid cTnT assay (< or = 10 min until assay positive) and CRP > or = 1.55 mg/dl had the highest mortality, followed by those with either CRP > or = 1.55 mg/dl or an early positive rapid cTnT assay, whereas patients with both a negative rapid cTnT assay and CRP < 1.55 mg/dl were at very low risk (9.10% vs. 4.65% vs. 0.36%, p = 0.0003). CONCLUSIONS: Elevated CRP at presentation in patients with unstable angina or NQMI is correlated with increased 14-day mortality, even in patients with a negative rapid cTnT assay. Quantitative CRP and a rapid cTnT assay provide complementary information for stratifying patients with regard to mortality risk.


This article has been cited by other articles:


Home page
Clin. Chem.Home page
M. P. Bonaca and D. A. Morrow
Defining a Role for Novel Biomarkers in Acute Coronary Syndromes
Clin. Chem., September 1, 2008; 54(9): 1424 - 1431.
[Abstract] [Full Text] [PDF]


Home page
QJMHome page
J. Sanchez-Quinones, F. Marin, V. Roldan, and G.Y.H. Lip
The impact of statin use on atrial fibrillation
QJM, August 24, 2008; (2008) hcn101v1.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. L. Mega, D. A. Morrow, J. A. de Lemos, S. Mohanavelu, C. P. Cannon, and M. S. Sabatine
Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes.
J. Am. Coll. Cardiol., June 24, 2008; 51(25): 2422 - 2429.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Bogaty, L. Boyer, S. Simard, F. Dauwe, R. Dupuis, B. Verret, T. Huynh, F. Bertrand, G. R. Dagenais, and J. M. Brophy
Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study.
J. Am. Coll. Cardiol., June 17, 2008; 51(24): 2339 - 2346.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
D. A. Morrow, M. S. Sabatine, M.-L. Brennan, J. A. de Lemos, S. A. Murphy, C. T. Ruff, N. Rifai, C. P. Cannon, and S. L. Hazen
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18
Eur. Heart J., May 1, 2008; 29(9): 1096 - 1102.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
H. O. Caymaz and G. Yuksel
Fate of Incidental, Asymptomatic Lesions Discovered During Percutaneous Coronary Intervention
Angiology, May 1, 2008; 59(2): 193 - 197.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
J. A. de Lemos, D. A. Morrow, M. A. Blazing, P. Jarolim, S. D. Wiviott, M. S. Sabatine, R. M. Califf, and E. Braunwald
Serial Measurement of Monocyte Chemoattractant Protein-1 After Acute Coronary Syndromes: Results From the A to Z Trial
J. Am. Coll. Cardiol., November 27, 2007; 50(22): 2117 - 2124.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
D. C. Grootendorst, D. J. de Jager, V. M. Brandenburg, E. W. Boeschoten, R. T. Krediet, F. W. Dekker, and The NECOSAD Study Group
Excellent agreement between C-reactive protein measurement methods in end-stage renal disease patients no additional power for mortality prediction with high-sensitivity CRP
Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3277 - 3284.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
B. M. Scirica, D. A. Morrow, C. P. Cannon, J. A. de Lemos, S. Murphy, M. S. Sabatine, S. D. Wiviott, N. Rifai, C. H. McCabe, E. Braunwald, et al.
Clinical Application of C-Reactive Protein Across the Spectrum of Acute Coronary Syndromes
Clin. Chem., October 1, 2007; 53(10): 1800 - 1807.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
F. G. Hage and A. J. Szalai
C-Reactive Protein Gene Polymorphisms, C-Reactive Protein Blood Levels, and Cardiovascular Disease Risk
J. Am. Coll. Cardiol., September 18, 2007; 50(12): 1115 - 1122.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al.
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157.
[Full Text] [PDF]


Home page
HeartHome page
J. Afilalo, A. A Majdan, and M. J Eisenberg
Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials
Heart, August 1, 2007; 93(8): 914 - 921.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al.
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660.
[Full Text] [PDF]


Home page
CirculationHome page
NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, and R. H. Christenson
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes
Circulation, April 3, 2007; 115(13): e356 - e375.
[Full Text] [PDF]


Home page
Eur Heart JHome page
K. K. Ray, C. P. Cannon, D. A. Morrow, A. J. Kirtane, J. Buros, N. Rifai, C. H. McCabe, C. M. Gibson, and E. Braunwald
Synergistic relationship between hyperglycaemia and inflammation with respect to clinical outcomes in non-ST-elevation acute coronary syndromes: analyses from OPUS-TIMI 16 and TACTICS-TIMI 18
Eur. Heart J., April 2, 2007; (2007) ehm010v1.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
NACB WRITING GROUP MEMBERS, D. A. Morrow, C. P. Cannon, R. L. Jesse, L. K. Newby, J. Ravkilde, A. B. Storrow, A. H.B. Wu, R. H. Christenson, NACB COMMITTEE MEMBERS, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes
Clin. Chem., April 1, 2007; 53(4): 552 - 574.
[Full Text] [PDF]


Home page
CirculationHome page
M. S. Sabatine, D. A. Morrow, K. A. Jablonski, M. M. Rice, J. W. Warnica, M. J. Domanski, J. Hsia, B. J. Gersh, N. Rifai, P. M Ridker, et al.
Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease
Circulation, March 27, 2007; 115(12): 1528 - 1536.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. Liuzzo, M. Santamaria, L. M. Biasucci, M. Narducci, V. Colafrancesco, A. Porto, S. Brugaletta, M. Pinnelli, V. Rizzello, A. Maseri, et al.
Persistent Activation of Nuclear Factor Kappa-B Signaling Pathway in Patients With Unstable Angina and Elevated Levels of C-Reactive Protein: Evidence for a Direct Proinflammatory Effect of Azide and Lipopolysaccharide-Free C-Reactive Protein on Human Monocytes Via Nuclear Factor Kappa-B Activation
J. Am. Coll. Cardiol., January 16, 2007; 49(2): 185 - 194.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
P. Libby and P. M. Ridker
Inflammation and Atherothrombosis: From Population Biology and Bench Research to Clinical Practice
J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A33 - A46.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. O'Donoghue, J. A. de Lemos, D. A. Morrow, S. A. Murphy, J. L. Buros, C. P. Cannon, and M. S. Sabatine
Prognostic Utility of Heart-Type Fatty Acid Binding Protein in Patients With Acute Coronary Syndromes
Circulation, August 8, 2006; 114(6): 550 - 557.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Tsimikas, J. T. Willerson, and P. M. Ridker
C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.
J. Am. Coll. Cardiol., April 18, 2006; 47(8 Suppl): C19 - C31.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
E. J. Armstrong, D. A. Morrow, and M. S. Sabatine
Inflammatory Biomarkers in Acute Coronary Syndromes: Part II: Acute-Phase Reactants and Biomarkers of Endothelial Cell Activation
Circulation, February 21, 2006; 113(7): e152 - e155.
[Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
S G Baidya and Q-T Zeng
Helper T cells and atherosclerosis: the cytokine web
Postgrad. Med. J., December 1, 2005; 81(962): 746 - 752.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. G. Lakoski, M. Cushman, W. Palmas, R. Blumenthal, R. B. D'Agostino Jr, and D. M. Herrington
The Relationship Between Blood Pressure and C-Reactive Protein in the Multi-Ethnic Study of Atherosclerosis (MESA)
J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1869 - 1874.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. S. Ginsburg, M. P. Donahue, and L. K. Newby
Prospects for Personalized Cardiovascular Medicine: The Impact of Genomics
J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1615 - 1627.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
N. Saleh, B. Svane, L.-O. Hansson, J. Jensen, T. Nilsson, O. Danielsson, and P. Tornvall
Response of Serum C-Reactive Protein to Percutaneous Coronary Intervention Has Prognostic Value
Clin. Chem., November 1, 2005; 51(11): 2124 - 2130.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. De Servi, M. Mariani, G. Mariani, and A. Mazzone
C-Reactive Protein Increase in Unstable Coronary Disease: Cause or Effect?
J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1496 - 1502.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Z. Mallat, Ph. G. Steg, J. Benessiano, M.-L. Tanguy, K. A. Fox, J.-P. Collet, O. H. Dabbous, P. Henry, K. F. Carruthers, A. Dauphin, et al.
Circulating Secretory Phospholipase A2 Activity Predicts Recurrent Events in Patients With Severe Acute Coronary Syndromes
J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1249 - 1257.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
L M Biasucci, G Giubilato, F Graziani, and M Piro
CRP is or is not a reliable marker of ischaemic heart disease?
Lupus, September 1, 2005; 14(9): 752 - 755.
[Abstract] [PDF]


Home page
Clin. Chem.Home page
J.-J. Li and C.-H. Fang
Effects of 4 Weeks of Atorvastatin Administration on the Antiinflammatory Cytokine Interleukin-10 in Patients with Unstable Angina
Clin. Chem., September 1, 2005; 51(9): 1735 - 1738.
[Full Text] [PDF]


Home page
Arch OphthalmolHome page
J. M. Seddon, S. George, B. Rosner, and N. Rifai
Progression of Age-Related Macular Degeneration: Prospective Assessment of C-Reactive Protein, Interleukin 6, and Other Cardiovascular Biomarkers
Arch Ophthalmol, June 1, 2005; 123(6): 774 - 782.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
T. J. Gluckman, M. Sachdev, S. P. Schulman, and R. S. Blumenthal
A Simplified Approach to the Management of Non-ST-Segment Elevation Acute Coronary Syndromes
JAMA, January 19, 2005; 293(3): 349 - 357.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
G. W. Vetrovec
Optimizing Percutaneous Coronary Intervention Outcomes: The Next Steps
Circulation, January 18, 2005; 111(2): 125 - 126.
[Full Text] [PDF]


Home page
CirculationHome page
R. Glaser, F. Selzer, D. P. Faxon, W. K. Laskey, H. A. Cohen, J. Slater, K. M. Detre, and R. L. Wilensky
Clinical Progression of Incidental, Asymptomatic Lesions Discovered During Culprit Vessel Coronary Intervention
Circulation, January 18, 2005; 111(2): 143 - 149.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
P. M Ridker, C. P. Cannon, D. Morrow, N. Rifai, L. M. Rose, C. H. McCabe, M. A. Pfeffer, E. Braunwald, and the Pravastatin or Atorvastatin Evaluation and Inf
C-Reactive Protein Levels and Outcomes after Statin Therapy
N. Engl. J. Med., January 6, 2005; 352(1): 20 - 28.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. Dokainish, M. Pillai, S. A. Murphy, P. M. DiBattiste, M. J. Schweiger, A. Lotfi, D. A. Morrow, C. P. Cannon, E. Braunwald, N. Lakkis, et al.
Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: A TACTICS-TIMI-18 substudy
J. Am. Coll. Cardiol., January 4, 2005; 45(1): 19 - 24.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. C. Smith Jr, J. L. Anderson, R. O. Cannon III, Y. Y. Fadl, W. Koenig, P. Libby, S. E. Lipshultz, G. A. Mensah, P. M Ridker, and R. Rosenson
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Report From the Clinical Practice Discussion Group
Circulation, December 21, 2004; 110(25): e550 - e553.
[Full Text] [PDF]


Home page
CirculationHome page
L. M. Biasucci
CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Clinical Use of Inflammatory Markers in Patients With Cardiovascular Diseases: A Background Paper
Circulation, December 21, 2004; 110(25): e560 - e567.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
F. S. Apple, M. M. Murakami, L. A. Pearce, and C. A. Herzog
Multi-Biomarker Risk Stratification of N-Terminal Pro-B-Type Natriuretic Peptide, High-Sensitivity C-Reactive Protein, and Cardiac Troponin T and I in End-Stage Renal Disease for All-Cause Death
Clin. Chem., December 1, 2004; 50(12): 2279 - 2285.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
B. S. Wiggins and S. Spinler
Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes
Journal of Pharmacy Practice, October 1, 2004; 17(5): 347 - 369.
[Abstract] [PDF]


Home page
Clin. Chem.Home page
L. M. Biasucci and G. G.L. Biondi-Zoccai
Preprocedural C-Reactive Protein for Risk Prediction Before Percutaneous Coronary Intervention (PCI): A European Perspective
Clin. Chem., September 1, 2004; 50(9): 1492 - 1494.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. L. Mega, D. A. Morrow, J. A. de Lemos, M. S. Sabatine, S. A. Murphy, N. Rifai, C. M. Gibson, E. M. Antman, and E. Braunwald
B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: An ENTIRE-TIMI-23 substudy
J. Am. Coll. Cardiol., July 21, 2004; 44(2): 335 - 339.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M. Panteghini
Role and importance of biochemical markers in clinical cardiology
Eur. Heart J., July 2, 2004; 25(14): 1187 - 1196.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Shimpo, D. A. Morrow, E. O. Weinberg, M. S. Sabatine, S. A. Murphy, E. M. Antman, and R. T. Lee
Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction
Circulation, May 11, 2004; 109(18): 2186 - 2190.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A.D. Booth, D.R.W. Jayne, R.K. Kharbanda, C.M. McEniery, I.S. Mackenzie, J. Brown, and I.B. Wilkinson
Infliximab Improves Endothelial Dysfunction in Systemic Vasculitis: A Model of Vascular Inflammation
Circulation, April 13, 2004; 109(14): 1718 - 1723.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. Sajadieh, O. W. Nielsen, V. Rasmussen, H. O. Hein, S. Abedini, and J. F. Hansen
Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease
Eur. Heart J., March 1, 2004; 25(5): 363 - 370.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
P L Sanchez, J L Morinigo, P Pabon, F Martin, I Piedra, I F Palacios, and C Martin-Luengo
Prognostic relations between inflammatory markers and mortality in diabetic patients with non-ST elevation acute coronary syndrome
Heart, March 1, 2004; 90(3): 264 - 269.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. D. Wiviott, C. P. Cannon, D. A. Morrow, S. A. Murphy, C. M. Gibson, C. H. McCabe, M. S. Sabatine, N. Rifai, R. P. Giugliano, P. M. DiBattiste, et al.
Differential Expression of Cardiac Biomarkers by Gender in Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) Substudy
Circulation, February 10, 2004; 109(5): 580 - 586.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
C. Heeschen, S. Dimmeler, S. Fichtlscherer, C. W. Hamm, J. Berger, M. L. Simoons, and A. M. Zeiher
Prognostic Value of Placental Growth Factor in Patients With Acute Chest Pain
JAMA, January 28, 2004; 291(4): 435 - 441.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. M Ridker and on behalf of the JUPITER Study Group
Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein: Rationale and Design of the JUPITER Trial*
Circulation, November 11, 2003; 108(19): 2292 - 2297.
[Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
G. J. Blake and P. M. Ridker
C-reactive protein: a surrogate risk marker or mediator of atherothrombosis?
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2003; 285(5): R1250 - R1252.
[Full Text] [PDF]


Home page
HeartHome page
S Kennon, A D Timmis, R Whitbourn, and C Knight
C reactive protein for risk stratification in acute coronary syndromes? Verdict: unproven
Heart, November 1, 2003; 89(11): 1288 - 1290.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
S. Kinlay, G. G. Schwartz, A. G. Olsson, N. Rifai, S. J. Leslie, W. J. Sasiela, M. Szarek, P. Libby, P. Ganz, and for the Myocardial Ischemia Reduction with Aggress
High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study
Circulation, September 30, 2003; 108(13): 1560 - 1566.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. James and L. Wallentin
C-reactive protein provides independent prognostic information on short- and long-term mortality in patients with non-st elevation acute coronary syndrome: Reply
J. Am. Coll. Cardiol., September 17, 2003; 42(6): 1145 - 1146.
[Full Text] [PDF]


Home page
CirculationHome page
N. Varo, J. A. de Lemos, P. Libby, D. A. Morrow, S. A. Murphy, R. Nuzzo, C. M. Gibson, C. P. Cannon, E. Braunwald, and U. Schonbeck
Soluble CD40L: Risk Prediction After Acute Coronary Syndromes
Circulation, September 2, 2003; 108(9): 1049 - 1052.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
D Tousoulis, G Davies, C Stefanadis, P Toutouzas, and J A Ambrose
Inflammatory and thrombotic mechanisms in coronary atherosclerosis
Heart, September 1, 2003; 89(9): 993 - 997.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
T. B. Ledue and N. Rifai
Preanalytic and Analytic Sources of Variations in C-reactive Protein Measurement: Implications for Cardiovascular Disease Risk Assessment
Clin. Chem., August 1, 2003; 49(8): 1258 - 1271.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. A. Morrow and E. Braunwald
Future of Biomarkers in Acute Coronary Syndromes: Moving Toward a Multimarker Strategy
Circulation, July 22, 2003; 108(3): 250 - 252.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. Y.-M. Wang, J. Woo, C. W.-K. Lam, M. Wang, M. M.-M. Sea, S.-F. Lui, P. K.-T. Li, and J. Sanderson
Is a Single Time Point C-Reactive Protein Predictive of Outcome in Peritoneal Dialysis Patients?
J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1871 - 1879.
[Abstract] [Full Text] [PDF]